- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 40/30 - Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
Patent holdings for IPC class A61K 40/30
Total number of patents in this class: 98
10-year publication summary
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
2
|
16
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Allogene Therapeutics, Inc. | 152 |
5 |
| The Trustees of the University of Pennsylvania | 4328 |
3 |
| In8bio, Inc. | 21 |
3 |
| The Regents of the University of California | 20015 |
2 |
| Adaptimmune Limited | 189 |
2 |
| Baylor College of Medicine | 956 |
2 |
| FATE Therapeutics, Inc. | 207 |
2 |
| Ludwig Institute for Cancer Research Ltd | 189 |
2 |
| Poseida Therapeutics, Inc. | 132 |
2 |
| Research Institute at Nationwide Children's Hospital | 560 |
2 |
| The UAB Research Foundation | 644 |
2 |
| Sangamo Therapeutics, Inc. | 418 |
2 |
| Sana Biotechnology, Inc. | 155 |
2 |
| Instil Bio (UK) Limited | 39 |
2 |
| Adicet Therapeutics, Inc. | 38 |
2 |
| Janssen Pharmaceuticals, Inc. | 432 |
1 |
| Centre National de La Recherche Scientifique | 10476 |
1 |
| Amgen Inc. | 4093 |
1 |
| The Board of Trustees of the Leland Stanford Junior University | 6441 |
1 |
| Wisconsin Alumni Research Foundation | 3891 |
1 |
| Other owners | 58 |